Related Experiment Video
Updated: Mar 16, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
The Dual NOD1/NOD2 Agonism of Muropeptides Containing a Meso-Diaminopimelic Acid Residue
Yulia A Dagil1, Nikolai P Arbatsky1, Biana I Alkhazova2
1Laboratory of Clinical Immunology, National Research Center "Institute of Immunology of the Federal Medical-Biological Agency", Moscow, Russia.
Abstract:
Muropeptides are fragments of peptidoglycan that trigger innate immune responses by activating nucleotide-binding oligomerization domain (NOD) 1 and NOD2. Muropeptides from Gram-negative bacteria contain a meso-diaminopimelic acid (meso-DAP) residue in either a terminal or a non-terminal position. While the former ones are known to be recognized by NOD1, much less is known about recognition of muropeptides with non-terminal meso-DAP, which are most abundant moieties of Gram-negative peptidoglycans. Here, we developed a novel system to assess biological activity of muropeptides, based on CRISPR/Cas9-mediated knockout (KO) of NOD1 and NOD2 genes in modified HEK293T cells. Using NOD1/NOD2 knockout and overexpression systems, as well as human monocytes and macrophages, we refine the current view of muropeptide recognition. We show that NOD2 can recognize different natural muropeptides containing a meso-DAP residue (preferably in a non-terminal position), provided they are present at micromolar concentrations. NOD2 accepts muropeptides with long and branched peptide chains and requires an intact N-acetylmuramyl residue. Muropeptides with non-terminal meso-DAP can activate NOD1 as well, but, in this case, probably require peptidase pre-processing to expose the meso-DAP residue. Depending on NOD1/NOD2 ratio in specific cell types, meso-DAP-containing muropeptides can be recognized either primarily via NOD2 (in monocytes) or via NOD1 (in monocyte-derived macrophages and HEK293T-derived cells). The dual NOD1/NOD2 agonism of meso-DAP-containing muropeptides should be taken into account when assessing cellular responses to muropeptides and designing muropeptide immunostimulants and vaccine adjuvants.
Insights
Muropeptides containing meso-diaminopimelic acid (meso-DAP) activate nucleotide-binding oligomerization domain (NOD) 1 and NOD2. This study reveals NOD2 recognizes non-terminal meso-DAP muropeptides, influencing innate immunity and vaccine adjuvant design.
Area of Science:
- Immunology
- Microbiology
- Molecular Biology
Background:
- Muropeptides, peptidoglycan fragments, activate innate immunity via NOD1 and NOD2.
- Gram-negative bacteria muropeptides often feature non-terminal meso-diaminopimelic acid (meso-DAP), whose recognition is poorly understood.
- Understanding muropeptide recognition is crucial for innate immunity research and therapeutic development.
Purpose of the Study:
- To investigate the recognition of muropeptides with non-terminal meso-DAP by NOD1 and NOD2.
- To elucidate the role of NOD1 and NOD2 in sensing Gram-negative bacterial muropeptides.
- To refine the understanding of muropeptide-mediated immune activation.
Main Methods:
- Developed a novel system using CRISPR/Cas9-mediated knockout (KO) of NOD1 and NOD2 genes in HEK293T cells.
- Utilized NOD1/NOD2 knockout and overexpression systems.
- Employed human monocytes and macrophages for cellular response assessments.
Main Results:
- NOD2 recognizes various natural muropeptides with meso-DAP, preferably in non-terminal positions, at micromolar concentrations.
- NOD2 accepts muropeptides with long/branched peptide chains and requires an intact N-acetylmuramyl residue.
- Muropeptides with non-terminal meso-DAP can activate NOD1, potentially requiring peptidase pre-processing.
Conclusions:
- Meso-DAP-containing muropeptides exhibit dual NOD1/NOD2 agonism, with cell-type-specific primary recognition (NOD2 in monocytes, NOD1 in macrophages).
- Findings necessitate consideration of this dual recognition in evaluating cellular responses to muropeptides.
- Results inform the design of muropeptide-based immunostimulants and vaccine adjuvants.
More Related Videos
Related Concept Videos
Opioid Receptors: Overview
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Cholinergic Receptors: Muscarinic
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

